VCEL Vericel Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCEL

Price (delayed)

$44.75

Market cap

$2.29B

P/E Ratio

93.23

Dividend/share

N/A

EPS

$0.48

Enterprise value

$2.26B

?
Relative Growth: Rel. Growth: 98
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 33
Relative Profitability: Rel. Profitability: 74

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly ...

Highlights
The gross profit has grown by 25% YoY and by 4.5% from the previous quarter
The revenue has grown by 23% YoY and by 4.9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://vcel.com
Peers: RPRX NEOG

Key stats

What are the main financial stats of VCEL

VCEL stock price

How has the Vericel stock price performed over time
Intraday
-1.34%
1 week
-6.01%
1 month
-3.89%
1 year
23.31%
YTD
24.27%
QTD
0.58%

Financial performance

How have Vericel's revenue and profit performed over time
Revenue
$306.3M
Gross profit
$228.38M
Operating income
$18.24M
Net income
$24.22M
Gross margin
74.6%
Net margin
7.9%
The net margin has soared by 172% YoY and by 8% QoQ
The gross profit has grown by 25% YoY and by 4.5% from the previous quarter
The revenue has grown by 23% YoY and by 4.9% from the previous quarter
Vericel's operating income has increased by 16% QoQ

Price vs fundamentals

How does VCEL's price correlate with its fundamentals

Growth

What is Vericel's growth rate over time

Valuation

What is Vericel stock price valuation
VCEL P/E details
P/E
93.23
P/B
6.18
P/S
7.46
EV/EBIT
87.82
EV/EBITDA
51.28
EV/Sales
7.37
The EPS has grown by 12% from the previous quarter
The stock's P/E is 6% less than its last 4 quarters average of 99.4
VCEL's price to book (P/B) is 23% lower than its 5-year quarterly average of 8.0 but 19% higher than its last 4 quarters average of 5.2
The equity rose by 21% year-on-year and by 3.9% since the previous quarter
The revenue has grown by 23% YoY and by 4.9% from the previous quarter
VCEL's price to sales (P/S) is 18% lower than its 5-year quarterly average of 9.1 but 17% higher than its last 4 quarters average of 6.4

Efficiency

How efficient is Vericel business performance
Vericel's return on assets has surged by 194% YoY and by 9% QoQ
VCEL's ROE has soared by 176% YoY and by 8% from the previous quarter
The ROS has soared by 163% YoY and by 6% from the previous quarter
The ROIC is up by 13% since the previous quarter

Dividends

What is VCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCEL.

Financial health

How did Vericel financials performed over time
The total assets has increased by 15% YoY and by 3.5% QoQ
Vericel's total liabilities has increased by 3.1% YoY and by 2.7% from the previous quarter
The debt is 75% lower than the equity
Vericel's debt to equity has decreased by 24% YoY and by 7% from the previous quarter
The equity rose by 21% year-on-year and by 3.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.